Effects of Daratumumab on Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Are Planned to Receive Autologous Transplantation: What's the Relevance?
作者信息
Sgherza Nicola, Musto Pellegrino
机构信息
Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy.
Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.
出版信息
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024073. doi: 10.4084/MJHID.2024.073. eCollection 2024.
Abstract
摘要
相似文献
1
Effects of Daratumumab on Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Are Planned to Receive Autologous Transplantation: What's the Relevance?
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024073. doi: 10.4084/MJHID.2024.073. eCollection 2024.
2
[Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1016-1021. doi: 10.3760/cma.j.issn.0253-2727.2023.12.008.
3
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.
4
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
5
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Lancet Oncol. 2011 Dec;12(13):1195-203. doi: 10.1016/S1470-2045(11)70243-1. Epub 2011 Sep 29.
6
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2015 Oct;21(10):1808-14. doi: 10.1016/j.bbmt.2015.06.017. Epub 2015 Jul 3.
7
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
8
Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis.
Hematology. 2024 Dec;29(1):2343164. doi: 10.1080/16078454.2024.2343164. Epub 2024 Apr 23.
9
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.
Leuk Lymphoma. 2023 Dec;64(13):2140-2147. doi: 10.1080/10428194.2023.2253479. Epub 2023 Sep 1.
10
[Retrospective clinical study on cryopreservation-free integrated autologous hematopoietic stem cell transplantation model for newly diagnosed multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):488-494. doi: 10.3760/cma.j.cn121090-20230929-00152.
本文引用的文献
1
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy.
Ann Hematol. 2024 Oct;103(10):4345-4347. doi: 10.1007/s00277-024-05933-3. Epub 2024 Aug 22.
2
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review.
Pharmaceuticals (Basel). 2024 Jul 15;17(7):944. doi: 10.3390/ph17070944.
3
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis.
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024049. doi: 10.4084/MJHID.2024.049. eCollection 2024.
4
Impact of Daratumumab on Stem Cell Mobilization and Transplant in Patient with Newly Diagnosed Multiple Myeloma: A Real Word Single-Centre Study.
Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024041. doi: 10.4084/MJHID.2024.041. eCollection 2024.
5
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.
Bone Marrow Transplant. 2024 Jun;59(6):896-898. doi: 10.1038/s41409-024-02260-z. Epub 2024 Mar 9.
6
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma.
Ann Hematol. 2024 Oct;103(10):3839-3853. doi: 10.1007/s00277-024-05683-2. Epub 2024 Mar 6.
7
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.
Blood Transfus. 2024 Jul;22(4):328-337. doi: 10.2450/BloodTransfus.667.
8
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
9
Insight into the mechanism of CD34 cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.
Br J Haematol. 2024 Apr;204(4):1439-1449. doi: 10.1111/bjh.19141. Epub 2023 Oct 9.
10
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27.
Zotero 插件